by DivRank | May 14, 2025 | Downgrades
Citigroup has shifted AbbVie from Buy to Neutral, setting a new price target of \$205. The downgrade signals increased concern over the company’s drug pipeline and its vulnerability to shifts in U.S. healthcare policy. 🔬 While AbbVie remains a pharmaceutical...
by DivRank | May 13, 2025 | Downgrades
Johnson & Johnson (NYSE: JNJ) has been downgraded by Leerink Partners from “Outperform” to “Market Perform,” with a revised price target of $153. This change is driven largely by new regulatory risks surrounding one of its top-selling...
by DivRank | May 13, 2025 | Downgrades
Goldman Sachs has downgraded Brown & Brown from Buy to Neutral and revised its price target to $119. The move reflects a more tempered view on the company’s growth potential as its organic expansion begins to mirror broader industry trends. With the rapid...
by DivRank | May 12, 2025 | Downgrades
Goldman Sachs has shifted its stance on Warner Music Group (NASDAQ: WMG), moving the stock from “Buy” to “Neutral” with a revised price target of \$28. This follows a similar downgrade from Morgan Stanley and reflects a growing consensus on...
by DivRank | May 12, 2025 | Downgrades
Remember when Target tried to sell Men’s bikinis? I won’t forget. On May 12, 2025, Bernstein downgraded Target Corporation (NYSE: TGT) from “Market Perform” to “Underperform,” reducing its price target to $82 from...
by DivRank | May 12, 2025 | Downgrades
SLR Investment Corp. (NASDAQ: SLRC) recently experienced a shift in analyst sentiment, with Ladenburg Thalmann downgrading the stock from Buy to Neutral and setting a price target of \$16.50. This change reflects growing concerns over the sustainability of...
